Iovance (IOVA) Soars 30% After 2026 Guidance Raise

Iovance Biotherapeutics (IOVA) raised its 2026 revenue guidance to $410–420 million on Amtagvi demand, and its shares jumped more than 30% on September 29, 2026.

Lead

What Did Iovance Announce?

Iovance increased its 2026 revenue outlook by $55 million at the midpoint, to a range of $410–420 million. The company had previously guided to $350–370 million. Interim President and Chief Executive Officer Frederick Vogt said the record second quarter and sustained demand for Amtagvi and Proleukin drove the decision.

The update follows record second-quarter 2026 total product revenue of $99.3 million. The new range also sits above the roughly $403 million average forecast among Wall Street analysts. Gross margin has improved to about 56%, reflecting manufacturing efficiencies that the company says are accelerating its progress toward profitability.

Iovance expects to report third-quarter 2026 financial results in early November.

Why Did IOVA Shares Jump More Than 30%?

Shares surged because the guidance raise exceeded consensus and confirmed that commercial uptake of Amtagvi is accelerating. Cell therapies for solid tumors have been slow to scale, and Iovance's launch has been closely watched for evidence that the model can grow beyond early adopters.

Three factors stand out in the reaction:

• Guidance above expectations. A $410–420 million range clears the consensus figure by roughly $7–17 million.
• Margin improvement. A gross margin near 56% suggests the costly, patient-specific manufacturing process is becoming more efficient.
• Network growth. The company has expanded its authorized treatment center network to about 100 sites and targets at least 110 by the end of 2026.

Iovance is a small-cap biotech cancer stock, and such shares often move sharply when a commercial launch beats expectations. The gain reversed months of pressure tied to earlier concerns about launch pace.

How Does Amtagvi Fit Into Iovance's Strategy?

Amtagvi is an FDA-approved, one-time treatment for previously treated advanced melanoma, and it is now approved in three global markets. It is a tumor-infiltrating lymphocyte (TIL) therapy. Doctors remove a patient's tumor tissue, and the company expands the immune cells in its manufacturing facility before they are infused back into the patient.

Proleukin, an IL-2 therapy given as part of the Amtagvi regimen, adds a second revenue stream. It benefits directly as more patients are treated at authorized centers.

Beyond melanoma, lifileucel is advancing through registrational programs in new solid tumor indications. The pipeline also includes gene-edited and IL-12 tethered TIL therapies, along with next-generation IL-2 approaches. Success in additional cancers would widen the addressable patient population well beyond the current label.

What Comes Next for Iovance?

The next test is the third-quarter report, due in early November, which will show whether the quarterly run rate is tracking toward the raised range. Reaching $410–420 million requires sustained sequential growth from the $99.3 million recorded in the second quarter.

Execution on the treatment center expansion and further gross margin gains will shape the path to profitability. Leadership is another variable, since the company is currently led by an interim chief executive.

Outlook

Iovance's guidance raise to $410–420 million, backed by record second-quarter sales and a widening treatment center network, marked a turning point in how the market views the Amtagvi launch. The stock's 30% gain reflects that shift. Attention now moves to third-quarter results in early November and to progress in new solid tumor indications.